



ATCC STEM CELLS SOLUTIONS: Enabling Research Through Standards


Yukari Tokuyama, Ph.D.
Applications Scientist, ATCC
August 21, 2014




ATCC™ | THE ESSENTIALS OF LIFE SCIENCE RESEARCH
GLOBALLY DELIVERED™




Outline




Introduction to ATCC




Human induced Pluripotent Stem Cells (iPSCs)




ATCC iPSC Collection



Quality Standards and Characterization



Supporting Reagents and Products




About ATCC

- Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas, VA
- World's premiere biological materials resource and standards development organization
- ATCC collaborates with and supports the scientific community with industry-standard products and innovative solutions
- Broad range of biomaterials
 - Cell lines
 - Microorganisms
 - Native & synthetic nucleic acids
 - Reagents







Outline




Introduction to ATCC




Human induced Pluripotent Stem Cells (iPSCs)



ATCC iPSC Collection




Quality Standards and Characterization



Supporting Reagents and Products



What are iPSCs?





Yamanaka Factors

- Oct3/4^{1,2}
- Sox2^{1,2}
- Klf4¹
- Myc¹
- Nanog²
- Lin28²



The promise of iPSCs



Gene editing
correcting inherited diseases





ATCC iPSC Collection

- Intellectual Property (IP) licenses
 - iPS Academia Japan (iAJ): iPSC-related technology
 - Sendai Virus Technology: Integration-free reprogramming delivery system
- ATCC iPSC lines
 - Normal: Foreskin, Hepatic and Cardiac fibroblasts
 - Diseased: Down Syndrome, Cystic Fibrosis, Parkinson's Disease
 - Reference iPSCs: Ethnic diverse and gender
- Reprogramming methods used to introduce Yamanaka factors (Oct3/4, Sox2, Klf4 and Myc)
 - Integration: Retrovirus
 - Integration-free: Sendai virus, Episomal Plasmid




Normal human primary cells for reprogramming

- ATCC Primary Solutions provide complete culture reagents formulated for optimal cell growth, morphology, and functionality
- ATCC primary cells are provided at very low passage




Melanocytes

- Adult
- Neonatal




Keratinocytes

- Adult
- Neonatal



Dermal Fibroblasts

- Adult
- Neonatal
- Neonatal mitomycin C-treated



Hematopoietic cells

- CD 34+ cord blood
- CD 34+ bone mesenchymal
- Peripheral blood mononuclear
- Bone marrow mononuclear
- Peripheral CD14+ monocytes




ATCC iPSC Normal Collection

- iPSC lines derived from apparent normal donors
- Fully consent and licensed for research use
- All ATCC iPSC lines are pre-adapted to an optimized serum-free, xeno-free, feeder-free cell culture environment

| ATCC® No. | Designation | Reprogramming Method | Tissue of Origin | Disease |
|-----------|--------------|----------------------|---------------------|---------|
| ACS-1019™ | ATCC-DYS0100 | Sendai Virus | Foreskin Fibroblast | Normal |
| ACS-1020™ | ATCC-HYS0103 | Sendai Virus | Liver Fibroblast | Normal |
| ACS-1021™ | ATCC-CYS0105 | Sendai Virus | Heart Fibroblast | Normal |
| ACS-1007™ | ATCC-HYR0103 | Retrovirus | Liver Fibroblast | Normal |
| ACS-1011™ | ATCC-DYR0100 | Retrovirus | Foreskin Fibroblast | Normal |



ATCC Reference iPSC Collection



Creating Standards


- Control lines for better comparison of data
- Develop lines with gender and ethnic diversity
- Fully characterized differentiation potential
- Reprogrammed from bone marrow CD34+
- Footprint free, sendai virus reprogrammed



ATCC Reference iPSC Collection




| ATCC® No. | Designation | Gender | Ethnicity |
|-----------|--------------|--------|-----------------|
| ACS-1024™ | ATCC-BYS0110 | Male | African America |
| ACS-1028™ | ATCC-BYS0114 | Female | African America |
| ACS-1025™ | ATCC-BYS0111 | Male | Hispanic |
| ACS-1029™ | ATCC-BXS0115 | Female | Hispanic |
| ACS-1026™ | ATCC-BYS0112 | Male | Caucasian |
| ACS-1030™ | ATCC-BXS0116 | Female | Caucasian |
| ACS-1027™ | ATCC-BYS0113 | Male | Asian |
| ACS-1031™ | ATCC-BXS0117 | Female | Asian |







Outline




Introduction to ATCC




Human induced Pluripotent Stem Cells (iPSCs)



ATCC iPSC Collection



Quality Standards and Characterization



Supporting Reagents and Products



Quality standards

Quality attribute

Authentication

- Identity
- Karyotype
- Sterility
- Mycoplasma
- Viral Panel

Preservation

- Post thaw viability
- Morphology
- Growth
- Purity







Characterization

- Pluripotency expression
- Germ layer differentiation
- Transcriptome analysis



ATCC iPSCs monitored for pluripotency

| Pluripotency Markers | Reactivity |
|----------------------|------------|
| Nanog | + |
| Tra 1-60 | + |
| Tra 1-81 | + |
| SSEA-4 | + |
| SSEA-1 | - |






ATCC iPSCs maintain differentiation potential

Pluripotency:


Three germ layer differentiation by EB formation





PluriTest™: ATCC iPSCs deemed pluripotent

Bioinformatic Analysis: Assesses pluripotency and differentiation based on a comparison of gene expression profiles from a large database of known samples



Pluripotency Score

Sample contains pluripotent signature

Novelty Score

Based on existing data from well-characterized PSC lines data

- ATCC iPSC lines
- Somatic cells used for reprogramming (HFF, CD34+)
- EBs 2, 3 and 4 weeks
- BG01V hESC (karyotypically abnormal)



ATCC Disease iPSC Collection

- iPSC lines derived from donors with diseases
- Fully consent and licensed for research use
- All ATCC iPSC lines are pre-adapted to an optimized serum-free, xeno-free, feeder-free cell culture environment

| ATCC® No. | Designation | Reprogramming Method | Tissue of Origin | Disease |
|-----------|--------------|----------------------|------------------|---|
| ACS-1012™ | ATCC-DYR0530 | Retrovirus | Skin | Parkinson's Disease, Asthma, Depression |
| ACS-1013™ | ATCC-DYS0530 | Sendai viral | Skin | Parkinson's Disease, Asthma, Depression |
| ACS-1014™ | ATCC-DYP0530 | Episomal | Skin | Parkinson's Disease, Asthma, Depression |
| ACS-1003™ | ATCC-DYP0730 | Episomal | Foreskin | Down syndrome |
| ACS-1004™ | ATCC-DYP0250 | Episomal | Skin | Cystic fibrosis: homozygous for CFTR Δ508 |



ATCC Parkinson's iPSC lines

Patient-specific iPSCs provide an opportunity to model human disease in culture 'Disease-in-a-dish'


- **Parkinson's Disease**

- Second most common neurodegenerative disorder
- Selective degeneration of dopaminergic neurons in the substantia nigra

- **Donor information:** 63 years old Caucasian male diagnosed with Parkinson's disease, asthma, and depression





- Exome sequencing identified multiple missense mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) gene: R50H, I1723V, M2397T

| ATCC® No. | Designation | Reprogramming method |
|-----------|--------------|----------------------|
| ACS-1012™ | ATCC-DYR0530 | Retrovirus |
| ACS-1013™ | ATCC-DYS0530 | Sendai virus |
| ACS-1014™ | ATCC-DYP0530 | Episomal |





Reprogramming methods do not affect differentiation potential




Nestin (red)
DAPI (blue)



Identification of missense mutations in Parkinson's hiPSC lines by exome sequencing

| Cell line | Reprogramming method | Passage # | Mutation # | Shared mutations with fibroblast | Shared mutations with ACS-1012™ | Shared mutations with ACS-1013™ | Shared mutations with ACS-1014™ |
|----------------------|----------------------|-----------|------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Parental Fibroblasts | N/A | P5 | 319 | N/A | 77% | 78% | 80% |
| ACS-1012™ | Retroviral | P13 | 325 | 75% | N/A | 74% | 77% |
| ACS-1013™ | Sendai viral | P12 | 310 | 81% | 77% | N/A | 83% |
| ACS-1014™ | Episomal | P16 | 362 | 71% | 69% | 71% | N/A |





Conserved gene mutations among Parkinson's iPSC lines

| Gene symbol | | | | | | | | | |
|-------------|---------|------------|---------------|---------|---------|-----------|----------|----------|---------|
| ABCA7 | C3orf20 | DHRS2 | GCC1 | L3MBTL4 | NARG2 | PLCB4 | SDK2 | SPTBN4 | UBR4 |
| ACCN5 | CACNA1B | DISP2 | GLIS3 | LACTB | NASP | PLEKHG2 | SEC24C | SRC | UGT1A4 |
| ACER1 | CCM2 | DNAH10 | GRB10 | LAMA5 | NCAPH2 | PMEPA1 | SEMA3G | SSPO | UMODL1 |
| ADNP2 | CD28 | DNAH2 | HCLS1 | LAMC3 | NDUFAF1 | PNCK | SEMA4A | STAT2 | UNC13A |
| AHDC1 | CDC45 | DNAH3 | IAH1 | LCP1 | NGF | PNPLA2 | SERPINA1 | STX8 | UPK3B |
| ALDH1L1 | CENPF | DNAH7 | IER5 | LGR5 | NLRP8 | POLDIP3 | SERTAD4 | SYDE2 | USP53 |
| ALKBH8 | CHAF1A | DNAI1 | IMPG1 | LRP2 | NLRX1 | POLQ | SHISA7 | SYNE1 | VGLL3 |
| ALMS1 | CHD6 | DNAJC11 | INHBE | LRRC66 | NPC1 | POLR2F | SIGLEC1 | TADA2A | VSIG10 |
| AMDHD2 | CLEC3B | DOCK2 | INPP5D | LRWD1 | NWD1 | PRRC2B | SIVA1 | TBC1D30 | VTA1 |
| AMPH | CLIC6 | DYRK1B | IPO13 | MAPK12 | OAZ1 | PRSS1 | SLC26A2 | TBL3 | VVA5B1 |
| ANO7 | CMA1 | EHD2 | JMJD7 | MBTPS1 | OGFR | PRSS2 | SLC45A4 | TC2N | WBSCR16 |
| AP3B2 | CNNM3 | ERVMER34-1 | JMJD7-PLA2G4B | MDGA2 | OR4C15 | PRSS3 | SLC5A1 | TDRD12 | WDFY1 |
| ARHGAP4 | CNTNAP4 | F5 | KCNAB1 | MDN1 | OR4L1 | PRX | SLC7A2 | TEP1 | WDR65 |
| ARHGEF19 | COBL1 | FAM120A | KCNK10 | MEF2A | OSBPL2 | PTPRN2 | SMCR8 | TEX15 | ZNF250 |
| ATP1A4 | COL14A1 | FAM178A | KIAA0232 | MILR1 | PABPC1 | RAB11FIP4 | SNPH | TIAM2 | ZNF469 |
| ATP9B | COL27A1 | FAM186A | KIAA1274 | MKNK2 | PCDHGA3 | RANGAP1 | SOLH | TM9SF1 | ZNF507 |
| BSND | CRLS1 | FAM208B | KIF17 | MPG | PDE4C | RCOR2 | SPAG1 | TMEM2 | ZNF629 |
| C10orf27 | CSF1 | FAM63A | KIF20B | MPPE1 | PIAS4 | REN | SPEF1 | TMEM60 | ZNF679 |
| C14orf49 | CSMD1 | FAM71D | KIF7 | MSLN | PILRA | RFXANK | SPEM1 | TNFRSF1B | ZNF717 |
| C18orf8 | DBT | FAM91A1 | KITLG | MUC16 | PKMYT1 | RIF1 | SPEN | TPRG1 | ZNF783 |
| C1QA | DCAKD | FBXO44 | KRTAP9-1 | MUC17 | PKNOX2 | RNF219 | SPTB | TRANK1 | ZNF804B |
| C1orf127 | | FCGBP | | MUC6 | | RNLS | | TRIM59 | ZNF880 |
| C20orf132 | | FITM1 | | MYL6 | | RP1L1 | | TRMT2A | ZSWIM2 |
| C2CD4B | | FN3K | | N4BP2L2 | | SDCCAG3 | | TSPYL4 | LRRK2 |




Disease-related mutations in Parkinson's iPSCs


| Gene symbol | Protein function | Gene mutation-associated disease |
|-------------|--|--|
| NPC1 | Maintaining the structural and functional integrity of nerve terminals | Autosomal recessive neurodegenerative disorder |
| NGF | Neural plasticity and apoptosis of neurons | Hereditary sensory and autonomic neuropathy |
| LRP2 | HDL endocytosis | Donai-Barrow syndrome |
| MEF2A | Neural differentiation and survival | Autosomal dominant coronary artery disease 1 |
| LRP2 | Regulation of HDL endocytosis | Doonai-Barrow Syndrome |
| MEF2A | Neural differentiation and survival | Autosomal dominant coronary artery disease 1 |
| DNAI1 | Regulation of dynein activity | Primary ciliary dyskinesia and kartagener syndrome |
| SLC5A1 | Sodium/glucose cotransporter | Glucose-galactose malabsorption |
| RP1L1 | Differentiation of photoreceptor cells | Macular dystrophy |
| PNPLA2 | Hydrolysis of triglycerides | Neutral lipid storage disease with myopathy |
| DBT | Amino acid metabolism | Maple syrup urine disease |
| BSND | Chloride reabsorption | Bartter syndrome |
| ZNF469 | Regulator of collagen fibers | Cornea syndrome |




Outline




Introduction to ATCC




Human induced Pluripotent Stem Cells (iPSCs)



ATCC iPSC Collection




Quality Standards and Characterization



Supporting Reagents and Products




Supporting reagents and products



Complete Culture Systems

- Feeder-Free: serum-free, xeno-free
- Feeder-Dependent: serum-free, xeno-free
- Conventional: DMEM/F12, ES qualified FBS
- Antibiotics-Free



Transfection Reagents

- GeneXPlus: Xeno-free
- TransfeX™: Xeno-free, hard-to-transfect cell lines
- Low cytotoxicity: balanced cytotoxicity and potency
- Performance tested



CoolCell®

- Alcohol-free cell freezing container
- Standardized controlled rate $-1^{\circ}\text{C}/\text{minute}$
- High post-thaw viability and proliferation
- 4 hours at -80°C before transfer to liquid nitrogen




Supporting reagents and products

No adaptation necessary, all reagents are formulated to work together!

| | Feeder-Free | Feeder-Dependent | Conventional |
|-------------------------------|---|--|---|
| Media | Pluripotent Stem Cell SFM XF/FF (Serum Free, Xeno Free) | Pluripotent Stem Cell SFM XF (Serum Free, Xeno Free) | Home Brew DMEM:F12 ES Qualified FBS |
| Substrate | Cell Basement Membrane | MEF/HFF Mitomycin C treated; γ -irradiated | MEF/HFF Mitomycin C treated; γ -irradiated |
| Passaging | Dissociation Reagent | Dissociation Reagent | Dissociation Reagent |
| Cryopreservation | Stem Cell Freezing Media | Stem Cell Freezing Media | Stem Cell Freezing Media |
| Supporting Reagent | ROCK inhibitor | ROCK inhibitor | ROCK inhibitor |




ATCC Media system is reliable and consistent






Supporting reagents and products



Complete Culture Systems

- Feeder-Free: serum-free, xeno-free
- Feeder-Dependent: serum-free, xeno-free
- Conventional: DMEM/F12, ES qualified FBS
- Antibiotics-Free



Transfection Reagents

- *GeneXPlus*: Xeno-free
- *TransfeX*: Xeno-free, hard-to-transfect cell lines
- Low cytotoxicity: balanced cytotoxicity and potency
- Performance tested



CoolCell®


- Alcohol-free cell freezing container
- Standardized controlled rate $-1^{\circ}\text{C}/\text{minute}$
- High post-thaw viability and proliferation
- 4 hours at -80°C before transfer to liquid nitrogen



ATCC TransfeX transfection reagent (ACS-4005)

TransfeX Reagent is:


- Designed for hard-to-transfect cell lines
- Validated in many iPSCs, adult stem cells, primary cells, immortalized cell lines, and continuous cell lines
- Free from animal components
- Performance tested





Transfection of dermal fibroblasts with TransfeX


Transfected with EF1 α -GFP vector





Transfection of hiPSCs with TransfeX


Transfected with EF1 α -GFP vector






ATCC TransfeX transfection guide

Protocols for using TransfeX to transfect . . .




Continuous

MDA-MB-231
HepG2 ▪ LNCap
Caco-2 ▪ C2C12
3T3-L1
NuLi-1 ▪ TIME
RPTEC-hTERT
hTERT-HME



Stem

Bone marrow-derived MSCs
hiPSCs
BT-142



Primary


Dermal Fibroblasts
Dermal Microvascular
Endothelial
HUVECs
RPTECs
Large Airway Epithelial
hMECs

Download this and our other free culture guides at www.atcc.org.

Contact Technical Service at tech@atcc.org




Supporting Reagents and Products



Complete Culture Systems

- Feeder-Free: serum-free, xeno-free
- Feeder-Dependent: serum-free, xeno-free
- Conventional: DMEM/F12, ES qualified FBS
- Antibiotics-Free



Transfection Reagents

- GeneXPlus: Xeno-free
- TransfeX™: Xeno-free, hard-to-transfect cell lines
- Low cytotoxicity: balanced cytotoxicity and potency
- Performance tested




CoolCell®

- Alcohol-free cell freezing container
- Standardized controlled rate $-1^{\circ}\text{C}/\text{minute}$
- High post-thaw viability and proliferation
- 4 hours at -80°C before transfer to liquid nitrogen



CoolCell[®] LX - ATCC[®] ACS-6000

- Alcohol-free cell freezing container
 - Insulation foam
 - Radial symmetry
 - Heat transfer core to regulate heat loss
 - Freezing at rate of 1°C per/minute in -80°C freezer
- Cells ready for LN storage after 4 hours (compared to over night with Mr. Frosty)
- Ready after 15 minutes for re-use, Mr. Frosty can take hours to come back to room temp for re-use





ATCC – Your trusted source

- Human induced pluripotent stem cells collection
 - Normal, Diseased, Reference iPSC Collection
 - Quality Standards and Characterization
 - Complete Culture Systems
 - Feeder-Dependent culture system
 - Feeder-Free culture system
 - Conventional culture system
 - In-depth Characterization
- TransfeX
 - Universal transfection reagent that can be used to transfect difficult-to-transfect cells like stem and primary cells
 - High efficiency and low cytotoxicity
 - Cost effective and scalable

ATCC cell lines are authenticated, and quality control tested in media formulations which support optimal growth characteristics



Resources for iPSC culture

Never cultured stem cells before?

View the ATCC Excellence in Research Series “on demand” *Stem Cell Solutions*, presented by John Pulliam, Ph.D.

This webinar demonstrates helpful tips and solutions, including:

- Thawing
- Passaging
- Cryopreservation of stem cells



ATCC® Stem Cell Culture Guide – All the tips and techniques you’ll need to successfully culture any stem cell

You’ll find information for:

Characterization ▪ Cryopreservation ▪ Culturing ▪ Applications


Download this and our other free culture guides at www.atcc.org/guides





Thank you!

Register for more webinars in the ATCC® “*Excellence in Research*” webinar series at www.atcc.org/webinars.




September 11, 2014
10:00 AM, 3:00 PM ET

Dr. Shamaila Ashraf will discuss using ATCC® influenza research materials in the development and validation of novel preventative and therapeutic techniques



September 18, 2014
10:00 AM, 3:00 PM ET

Dr. Fang Tian and Dr. David H. Randall will talk about ATCC® Genetic Alterations Panels and how they can be effective tools in highput screening using Corning® Epic™ technology.



October 16, 2014
10:00 AM, 3:00 PM ET

Dr. Tigwa H. Davis will discuss using LUHMES cells as a model system to study dopaminergic neuron cell biology.

Thank you for joining today!
Please send additional questions to tech@atcc.org